HeartSciences
Indexed for what is commercially available today, which requires care because the company's own AI algorithms are not yet cleared. MyoVista Insights is a cloud based ECG reporting and management platform, in phased rollout since May 2025 and shipping at version 1.3 as of June 2026, positioned to replace on premise ECG management software. Its AI-ECG Algorithm Marketplace, introduced in version 1.3, integrates third party algorithm results into the platform, and the first algorithm made available is Bunkerhill Health's FDA cleared ECG-EF model detecting reduced left ventricular ejection fraction at or below 40 percent from a routine 12-lead ECG. Bunkerhill is separately indexed here, so this is a distribution relationship between two vendors in this index rather than a HeartSciences algorithm. The company's own pipeline is not yet available: the MyoVista wavECG device, a 12-lead resting ECG built to host AI-ECG algorithms, was submitted for 510(k) clearance in December 2025 and clearance was not confirmed at the time of this record; its impaired cardiac relaxation algorithm was deliberately separated from that submission to complete additional validation against revised American Society of Echocardiography guidelines for diastolic dysfunction; and its low ejection fraction algorithm remains in pre submission work. Underlying intellectual property is licensed in part from the Icahn School of Medicine at Mount Sinai. Assistive AI-ECG assessments are eligible for Medicare reimbursement under the Hospital Outpatient Prospective Payment System at APC 5734. NASDAQ: HSCS.
Capability Axes
This grade reflects a distinction the company's marketing does not make. What a facility can buy today is an ECG reporting and management platform, and the AI available through it is a third party algorithm from Bunkerhill Health, separately indexed here. HeartSciences' own AI-ECG algorithms, impaired cardiac relaxation and low ejection fraction, are not cleared and not commercially available. A buyer purchasing MyoVista Insights in 2026 is buying ECG workflow software plus access to someone else's cleared model.
Thin, and the company is candid about the stage. The platform has been in phased rollout since May 2025 at early adopter reference sites, with the company describing itself as engaged in commercial discussions and expecting to announce initial customer deployments as they progress. No named customer, deployment count, or outcome data was retrieved. A multi center clinical study supporting the impaired cardiac relaxation algorithm has completed recruitment but supports a product that is not yet available.
The status is genuinely mixed and the company reports it clearly, which is to its credit even though the grade is low. Cleared and available: none of its own. The Bunkerhill ECG-EF algorithm distributed through the marketplace is FDA cleared, but that clearance belongs to Bunkerhill. Submitted, not cleared: the MyoVista wavECG device, filed for 510(k) in December 2025. In development: the impaired cardiac relaxation algorithm, deliberately pulled from that submission to revalidate against revised American Society of Echocardiography guidelines on diastolic dysfunction, and the low ejection fraction algorithm still in pre submission. Separating device and algorithm submissions is sound regulatory strategy and the company explains why. Under this index's product maturity rule, none of the company's own algorithms qualify as shipping capability.
Better than most in this index on structure, which matters more than a rate card here. The marketplace is described as a recurring SaaS model, positioned as a commercial route for AI-ECG developers to reach clinical users without building their own distribution. The company also states the reimbursement pathway explicitly: assistive AI-ECG assessments are eligible under the Hospital Outpatient Prospective Payment System at APC 5734. Naming the payment classification lets a buyer model revenue offset directly, which very few vendors here enable. Held back from A because no price is published.
Tightly bounded to cardiology and specifically to the 12-lead resting ECG, with a deliberate emphasis on reach: the marketplace is positioned to make cleared AI-ECG algorithms available to facilities of every size, from integrated health systems down to community hospitals, critical access hospitals, and primary care practices. Extending algorithm access below the large health system tier is the substantive access argument, since that is where cardiology imaging is least available.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Recurring SaaS platform subscription; marketplace distribution for third-party algorithms | — | — | Vendor Published |
No rate card published, but the commercial model is stated: recurring SaaS for the MyoVista Insights platform, with the AI-ECG Algorithm Marketplace acting as a distribution channel for third party algorithm developers. Two things a buyer should establish. First, what is included today: the cleared AI available through the platform is Bunkerhill Health's ECG-EF model, not a HeartSciences algorithm, and the company's own algorithms are not cleared. Second, reimbursement offset: the company states assistive AI-ECG assessments are eligible under the Hospital Outpatient Prospective Payment System at APC 5734, which allows a facility to model revenue against subscription cost rather than treating it as pure expense.